skip to main content

Prostate Cancer

New target for prostate cancer resistant to anti-hormone therapies

Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.

Researchers from the University of Michigan Rogel Cancer Center have found that a protein called BET bromodomain protein 4 binds to the hormone androgen receptor downstream of where current therapies work – targeting androgen receptor signaling.

Intermittent hormone therapy for prostate cancer inferior to continuous therapy

Over men 1200 men with metastatic, hormone-sensitive prostate cancer were given intermittent androgen-deprivation (AD) therapy after seven months of androgen deprivation. The results show intermittent hormone therapy offers some quality-of-life benefits, but lower overall survival.

The Weight Battle

Dietitians offer strategies for controlling weight after cancer treatment